Zentalis Pharmaceuticals, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $295.00K, a 56.08% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $0.00.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $115.00K, a 25.00% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $304.00K, a 10.59% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $340.00K, a 45.86% decline from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $628.00K, a 28.15% decline from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $874.00K, a 60.37% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $410.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $295.00K 10-Q · filed 2026-05-12 | $410.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $304.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $115.00K 10-Q · filed 2025-11-10 | $304.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $281.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $189.00K 10-Q · filed 2026-05-12 | $281.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $340.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $92.00K 10-Q · filed 2025-11-10 | $340.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $503.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | $248.00K 10-Q · filed 2025-05-14 | $503.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $628.00K 10-K · filed 2026-03-26 |
| 2023-09-30 | $255.00K 10-Q · filed 2024-11-12 | $628.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $635.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $373.00K 10-Q · filed 2024-05-07 | $635.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $874.00K 10-K · filed 2025-03-26 |
| 2022-09-30 | $262.00K 10-Q · filed 2023-11-06 | $874.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.16M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $612.00K 10-Q · filed 2023-05-10 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $545.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $545.00K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |